Tirzepatide: Everything You Need to Know Before Starting

Semaglutide is a single GLP-1 receptor agonist, it targets one hormone pathway. Tirzepatide is a dual GIP and GLP-1 receptor agonist, it targets two hormone pathways simultaneously. GIP (glucose-dependent insulinotropic polypeptide) is an incretin hormone that works synergistically with GLP-1 to improve insulin sensitivity, enhance fat metabolism, and reduce appetite. Clinical trials suggest that this dual mechanism produces greater average weight reduction: up to 22.5% with tirzepatide versus 15-17% with semaglutide. Both are effective; tirzepatide may offer enhanced results for some patients.

There is no universal answer. Tirzepatide showed greater average weight loss in clinical trials (up to 22.5% vs 15-17%), but individual responses vary significantly. Some patients respond better to semaglutide, others to tirzepatide. Factors include your metabolic profile, insulin resistance status, side effect tolerance, and treatment goals. Your FormBlends physician evaluates your specific health picture and recommends the option most likely to work for your biology. Some members start with one and switch to the other based on response.

Both medications share a similar side effect profile: nausea, reduced appetite, diarrhea, vomiting, and constipation. These are most common during dose escalation and typically diminish over time. Some studies suggest that gastrointestinal side effects may be slightly more frequent with tirzepatide at higher doses, though this varies by individual. Proper titration, starting low and increasing gradually, significantly reduces side effect severity for both medications. Your FormBlends physician adjusts your protocol based on your tolerance.

Tirzepatide is injected subcutaneously once weekly. The standard titration begins at 2.5mg weekly for 4 weeks, then increases to 5mg weekly for 4 weeks, with potential further increases to 7.5mg, 10mg, 12.5mg, or 15mg based on response and tolerance. Each dose increase is held for at least 4 weeks before further escalation. Your FormBlends physician personalizes this schedule, some patients achieve excellent results at lower doses and never need to escalate to the maximum.

Yes. FormBlends offers compounded tirzepatide prepared by licensed 503A compounding pharmacies. Compounded tirzepatide contains tirzepatide as its active ingredient. It is not FDA-approved as a finished product. As with all compounded medications, the finished product is not FDA-approved, though it is manufactured under cGMP standards with third-party potency and purity testing. Your physician determines whether semaglutide or tirzepatide is the better fit for your specific situation.

Tirzepatide may be particularly effective for patients with significant insulin resistance, type 2 diabetes or prediabetes, or those who need greater weight reduction to address obesity-related comorbidities. The dual GIP/GLP-1 mechanism provides enhanced insulin sensitization that can be especially beneficial for metabolic health. Semaglutide may be preferred for patients who are more cost-sensitive, have milder weight management needs, or who want the benefit of longer real-world safety data. Your FormBlends physician considers all of these factors when making a recommendation.